| Literature DB >> 30961604 |
Vladeta Ajdacic-Gross1,2, Margot Mutsch3, Stephanie Rodgers4, Anja Tesic4, Mario Müller4, Erich Seifritz4, En-Young N Wagner5, Roland von Känel5, Markus A Landolt6,7, Nina Steinemann3, Viktor von Wyl3, Enrique Castelao8, Marie-Pierre F Strippoli8, Jennifer Glaus8,9, Caroline Vandeleur8, Pedro M Marques-Vidal10, Peter Vollenweider10, Martin Preisig8.
Abstract
BACKGROUND: Comorbidity patterns of childhood infections, atopic diseases, and adverse childhood experiences (ACE) are related to immune system programming conditions. The aim of this study was to make a step beyond the hygiene hypothesis and to comprehensively classify these patterns with latent class analysis (LCA). A second aim was to characterize the classes by associations with immunological, clinical, and sociodemographic variables.Entities:
Keywords: Biomarkers; Chronic diseases; Hygiene hypothesis; Immune system; Latent class analysis; Mental disorders
Mesh:
Year: 2019 PMID: 30961604 PMCID: PMC6454751 DOI: 10.1186/s12916-019-1311-z
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1CoLaus|PsyCoLaus sample design
WBC counts and inflammatory markers in CoLaus|PsyCoLaus (mean and 95% confidence interval)
| All | Men | Women | |
|---|---|---|---|
| White blood cell counts1 | |||
| Total leukocytes (in 1000/mm3) | 6.25 (6.19–6.32) | 6.40 (6.30–6.49) | 6.13 (6.05–6.21) |
| Neutrophils % | 0.548 (0.545–0.551) | 0.545 (0.540–0.550) | 0.550 (0.546–0.555) |
| Basophils % | 0.0058 (0.0057–0.0059) | 0.0056 (0.0054–0.0057) | 0.0060 (0.0059–0.0062) |
| Eosinophils % | 0.0294 (0.0288–0.0301) | 0.0316 (0.0307–0.0326) | 0.0276 (0.0268–0.0284) |
| Lymphocytes % | 0.326 (0.323–0.329) | 0.321 (0.317–0.326) | 0.330 (0.326–0.334) |
| Monocytes % | 0.0868 (0.0860–0.0876) | 0.0924 (0.0912–0.0936) | 0.0821 (0.0812–0.0831) |
| Inflammatory markers at baseline | |||
| IL-6 (pg/ml) | 8.15 (6.46–9.84) | 8.11 (5.55–10.67) | 8.19 (5.93–10.44) |
| IL-1β (pg/ml) | 4.25 (3.49–5.02) | 4.31 (3.38–5.24) | 4.20 (3.03–5.38) |
| TNF-α (pg/ml) | 6.62 (4.95–8.29) | 5.52 (4.37–6.66) | 7.57 (4.62–10.53) |
| hsCRP (mg/l) | 1.81 (1.76–1.87) | 1.73 (1.65–1.80) | 1.89 (1.81–1.97) |
| Inflammatory markers at follow-up 1 | |||
| IL-6 (pg/ml) | 17.54 (15.39–19.69) | 17.53 (14.45–20.60) | 17.56 (14.56–20.55) |
| IL-1β (pg/ml) | 4.45 (3.84–5.06) | 4.53 (3.81–5.24) | 4.39 (3.45–5.34) |
| TNF-α (pg/ml) | 10.46 (8.44–12.47) | 10.08 (8.57–11.59) | 10.78 (7.27–14.29) |
| hsCRP (mg/l) | 1.89 (1.83–1.95) | 1.77 (1.69–1.85) | 1.98 (1.90–2.06) |
1WBC counts were assessed only at follow-up 1
Infections, atopies, and adverse childhood experiences in CoLaus|PsyCoLaus: frequencies and proportions
| All | Men | Women | |
|---|---|---|---|
| Infections | |||
| Chickenpox | 3733 (83.3%) | 1657 (80.8%) | 2076 (85.5%) |
| Measles | 3323 (75.7%) | 1442 (72.0%) | 1881 (78.8%) |
| Mumps | 2720 (60.8%) | 1291 (62.9%) | 1429 (59.1%) |
| Rubella | 283 (5.3%) | 62 (2.7%) | 221 (8.5%) |
| Scarlet fever | 216 (4.4%) | 80 (3.5%) | 136 (5.2%) |
| Pertussis | 377 (7.7%) | 113 (5.0%) | 264 (10.1%) |
| Herpes labialis | 767 (15.7%) | 260 (11.5%) | 507 (19.4%) |
| Atopies | |||
| Atopic asthma | 291 (6.0%) | 107 (4.7%) | 184 (7.0%) |
| Other asthma | 373 (7.7%) | 141 (6.2%) | 232 (8.9%) |
| Atopic eczema | 230 (4.7%) | 72 (3.2%) | 158 (6.1%) |
| Other eczema | 314 (6.4%) | 125 (5.5%) | 189 (7.2%) |
| Hay fever | 890 (18.3%) | 420 (18.6%) | 470 (18.0%) |
| Urticaria | 179 (3.7%) | 59 (2.6%) | 120 (4.6%) |
| Drug allergy | 493 (10.1%) | 164 (7.2%) | 329 (12.6) |
| Adverse childhood experiences | |||
| Fights among parents | 609 (12.6%) | 264 (11.8%) | 345 (13.4%) |
| Fear of parental maltreatment | 464 (9.6%) | 191 (8.5%) | 273 (10.5%) |
| Trauma below age of 10 | 189 (3.9%) | 56 (2.5%) | 133 (5.1%) |
Chronic inflammatory diseases and main groups of neurodevelopmental/mental disorders in CoLaus|PsyCoLaus: frequencies and proportions
| All | Men | Women | |
|---|---|---|---|
| Chronic inflammatory diseases | |||
| Ulcer | 265 (5.4%) | 136 (6.0%) | 129 (4.9%) |
| Irritable bowel syndrome | 188 (3.9%) | 52 (2.3%) | 136 (5.2%) |
| Cystitis | 1069 (21.9%) | 116 (5.1%) | 953 (36.5%) |
| Acne | 475 (9.7%) | 191 (8.4%) | 284 (10.9%) |
| Psoriasis | 220 (4.5%) | 108 (4.8%) | 112 (4.3%) |
| Migraine | 664 (13.6%) | 196 (8.7%) | 468 (17.9%) |
| Neurodevelopmental/mental disorders1 | |||
| Neurodevelopmental disorders | 353 (7.2%) | 214 (9.5%) | 139 (5.3%) |
| Early anxiety disorders | 1104 (22.7%) | 377 (16.7%) | 727 (27.9%) |
| Late anxiety disorders | 655 (16.2%) | 233 (10.3%) | 422 (16.2%) |
| Mood disorders | 2161 (44.3%) | 770 (34.0%) | 1391 (53.3%) |
| Substance disorders | 645 (13.2%) | 488 (21.6%) | 157 (6.0%) |
1Neurodevelopmental disorders: tics, attention-deficit hyperactivity disorder (ADHD), conduct disorder (CD), oppositional defiant disorder (ODD); early anxiety disorders: separation anxiety disorder, overanxious disorder, specific phobias (animals), social phobia; late anxiety disorders: generalized anxiety disorder (GAD), panic, agoraphobia, specific phobias (excl. animals); mood disorders: major depression disorder, dysthymia, bipolar disorders; substance disorders: alcohol, cannabis, other illicit drug abuse/dependence
Model fit indices for latent class analyses with one through six classes, men and women
| Fit statistics | 1-class model | 2-class model | 3-class model | 4-class model | 5-class model | 6-class model |
|---|---|---|---|---|---|---|
| Men | ||||||
| AIC | 21,775.3 | 21,055.2 | 20,801.7 | 20,639.2 | 20,604.3 | 20,599.4 |
| BIC | 21,872.7 | 21,255.5 | 21,105.1 | 21,045.7 | 21,113.8 | 21,211.9 |
| ABIC | 21,818.6 | 21,144.3 | 20,936.7 | 20,820.1 | 20,831.1 | 20,872.0 |
| LMR-LRT. adj. | 750.8 | 287.4 | 197.0 | 70.4 | 40.6 | |
| | < 0.001 | < 0.001 | 0.052 | 0.648 | 0.016 | |
| Women | ||||||
| AIC | 30,328.7 | 29,729.7 | 29,466.4 | 29,262.3 | 29,186.2 | 29,148.4 |
| BIC | 30,428.4 | 29,935.1 | 29,777.4 | 29,678.9 | 29,708.3 | 29,776.2 |
| ABIC | 30,374.4 | 29,823.8 | 29,609.0 | 29,453.3 | 29,425.6 | 29,436.2 |
| LMR-LRT. adj. | 630.5 | 297.2 | 238.4 | 111.4 | 73.2 | |
| | < 0.001 | < 0.001 | 0.003 | 0.002 | 0.106 | |
AIC Akaike information criterion, BIC Bayesian information criterion, ABIC sample size-adjusted Bayesian information criterion, LMR-LRT. adj. Lo-Mendell-Rubin likelihood ratio test—adjusted
Fig. 2Latent class analysis with infectious childhood diseases, atopic diseases, and childhood adversities in the PsyCoLaus study; probabilities of the five-class model, men
Fig. 3Latent class analysis with infectious childhood diseases, atopic diseases, and childhood adversities in the PsyCoLaus study; probabilities of the five-class model, women
Fig. 4Proportions of latent classes, men; overall and after median split
Fig. 5Proportions of latent classes, women; overall and after median split
Sociodemographic and socioeconomic characteristics of immune-mediated classes, men and women
| Neutral class | Resilient class | Atopic class | Mixed class | ACE class | Overall | |
|---|---|---|---|---|---|---|
| Men | ||||||
| | 1337 | 523 | 131 | 177 | 96 | 2264 |
| SES score | 3.56 (3.50–3.63) | 3.33 (3.23–3.44) | 3.93 (3.73–4.13) | 3.77 (3.60–3.94) | 3.27 (3.00–3.54) | 3.53 (3.48–3.59) |
| Mean age | 53.6 (53.0–54.2) | 54.4 (53.4–55.4) | 50.1 (48.2–51.9) | 53.3 (51.6–55.0) | 51.5 (49.3–53.6) | 53.5 (53.0–53.9) |
| Women | ||||||
| | 1512 | 509 | 186 | 255 | 148 | 2610 |
| SES score | 3.19 (3.12–3.25) | 3.20 (3.09–3.31) | 3.39 (3.21–3.57) | 3.44 (3.29–3.59) | 2.95 (2.73–3.16) | 3.21 (3.17–3.26) |
| Mean age | 54.7 (54.2–55.3) | 56.4 (55.4–57.5) | 51.9 (50.2–53.5) | 55.2 (54.0–56.5) | 51.1 (49.7–52.6) | 54.7 (54.3–55.1) |
ACE adverse childhood experiences, SES socioeconomic status (Hollingshead index)
Fig. 6White blood cell counts across latent classes, by sex; means (leukocytes) and proportions (specific white blood cells); data smoothed by square root
Fig. 7Mean ranks of inflammatory markers from two assessments, across latent classes, by sex
Odds ratios (95% confidence intervals) of somatic diseases/disorders (lifetime prevalence) regressed on immune-mediated classes, men and women
| Neutral class | Resilient class | Atopic class | Mixed class | ACE class | |
|---|---|---|---|---|---|
| Men | |||||
| Ulcer | 1 (ref.) | 1.6 (1.1–2.3) | 1.0 (0.4–2.1) | 0.7 (0.3–1.6) | 0.7 (0.3–2.1) |
| Irritable bowel syndrome | 1 (ref.) | 1.0 (0.5–2.1) | 3.0 (1.3–7.0) | 2.5 (1.1–5.6) | 1.1 (0.3–4.8) |
| Cystitis | 1 (ref.) | 0.7 (0.4–1.3) | 3.2 (1.8–5.7) | 3.3 (1.9–5.5) | 1.5 (0.6–3.6) |
| Acne | 1 (ref.) | 0.7 (0.5–1.1) | 1.4 (0.8–2.5) | 1.8 (1.1–2.8) | 0.7 (0.3–1.7) |
| Psoriasis | 1 (ref.) | 0.7 (0.4–1.1) | 0.3 (0.1–1.2) | 1.3 (0.7–2.5) | 1.2 (0.5–2.9) |
| Migraine | 1 (ref.) | 1.1 (0.7–1.6) | 1.8 (1.1–3.2) | 2.3 (1.5–3.6) | 1.3 (0.6–2.6) |
| Women | |||||
| Ulcer | 1 (ref.) | 1.3 (0.8–2.1) | 1.5 (0.8–2.9) | 1.4 (0.8–2.5) | 3.1 (1.8–5.4) |
| Irritable bowel syndrome | 1 (ref.) | 1.5 (0.9–2.4) | 2.0 (1.1–3.8) | 2.9 (1.8–4.8) | 3.7 (2.1–6.6) |
| Cystitis | 1 (ref.) | 1.0 (0.8–1.2) | 2.1 (1.5–2.8) | 1.9 (1.5–2.5) | 2.2 (1.5–3.0) |
| Acne | 1 (ref.) | 0.9 (0.6–1.3) | 1.1 (0.6–1.7) | 1.5 (1.0–2.2) | 1.8 (1.1–2.8) |
| Psoriasis | 1 (ref.) | 0.9 (0.5–1.5) | 1.0 (0.5–2.1) | 0.9 (0.5–1.8) | 1.6 (0.8–3.2) |
| Migraine | 1 (ref.) | 0.9 (0.7–1.2) | 1.7 (1.2–2.4) | 1.2 (0.9–1.7) | 1.2 (0.8–1.8) |
ACE adverse childhood experiences
Odds ratios (95% confidence intervals) of groups of mental disorders (lifetime prevalence) regressed on immune-mediated classes, men and women
| Neutral class | Resilient class | Atopic class | Mixed class | ACE class | |
|---|---|---|---|---|---|
| Men | |||||
| Neurodevelopmental disorders | 1 (ref.) | 0.8 (0.5–1.2) | 1.7 (1.0–3.0) | 2.0 (1.3–3.2) | 4.0 (2.4–6.5) |
| Early anxiety disorders | 1 (ref.) | 0.8 (0.6–1.1) | 1.1 (0.7–1.8) | 2.0 (1.4–2.8) | 2.7 (1.7–4.3) |
| Late anxiety disorders | 1 (ref.) | 0.7 (0.5–1.0) | 1.2 (0.7–2.1) | 1.5 (1.0–2.4) | 1.6 (0.9–2.9) |
| Mood disorders | 1 (ref.) | 0.8 (0.7–1.0) | 1.5 (1.0–2.2) | 1.8 (1.3–2.5) | 2.3 (1.5–3.4) |
| Substance disorders | 1 (ref.) | 0.9 (0.7–1.2) | 1.1 (0.7–1.6) | 1.1 (0.8–1.6) | 1.8 (1.1–2.8) |
| Women | |||||
| Neurodevelopmental disorders | 1 (ref.) | 0.6 (0.3–1.0) | 0.9 (0.4–1.8) | 1.6 (0.9–2.6) | 3.8 (2.3–6.2) |
| Early anxiety disorders | 1 (ref.) | 0.7 (0.5–0.9) | 1.6 (1.2–2.2) | 1.4 (1.1–1.9) | 3.0 (2.1–4.2) |
| Late anxiety disorders | 1 (ref.) | 0.8 (0.6–1.1) | 1.2 (0.8–1.8) | 1.6 (1.1–2.2) | 2.7 (1.9–4.0) |
| Mood disorders | 1 (ref.) | 0.9 (0.7–1.0) | 1.1 (0.8–1.5) | 1.4 (1.1–1.9) | 2.2 (1.5–3.2) |
| Substance disorders | 1 (ref.) | 0.6 (0.4–1.0) | 1.8 (1.0–3.0) | 1.6 (1.0–2.6) | 2.7 (1.6–4.6) |
ACE adverse childhood experiences
Groups of mental disorders: neurodevelopmental disorders—tics, attention-deficit hyperactivity disorder, conduct disorder, oppositional defiant disorder; early anxiety disorders—separation anxiety disorder, overanxious disorder, specific phobias (animals), social phobia; late anxiety disorders—generalized anxiety disorder, panic, agoraphobia, specific phobias (excl. animals); mood disorders—major depression disorder, dysthymia, bipolar disorders; substance disorders—alcohol, cannabis, other illicit drug abuse/dependence